PPARγ and GLP1 Agonists Improve Brain Metabolism, NDEV Biomarkers Reveal

Metabolic dysfunction is increasingly recognized as a key contributor to neurodegenerative diseases and cognitive decline, impacting brain energy utilization. PPARγ agonists (like pioglitazone) and GLP1 receptor agonists (like liraglutide) are well-established for their benefits on peripheral metabolism, including glucose control and insulin sensitivity. However, their direct impact on brain metabolism and the utility of novel NDEV (Neuro-Derived Extracellular Vesicle) biomarkers to monitor these effects in humans remain less understood.

Both pioglitazone and liraglutide significantly improved brain glucose metabolism compared to the placebo group. The pioglitazone group showed a 25% increase in brain glucose uptake (measured by FDG-PET) and a 30% reduction in inflammatory NDEV markers (e.g., TNF-α within NDEVs, p<0.01). The liraglutide group demonstrated a 20% increase in brain glucose uptake and a 28% decrease in NDEV markers associated with oxidative stress (e.g., 4-HNE within NDEVs, p<0.05). > The most significant finding was a 40% increase in mitochondrial complex I activity within NDEV samples from both active treatment groups, indicating enhanced neuronal energy production compared to placebo (p<0.001). These improvements were correlated with peripheral metabolic markers, including a 15% decrease in HbA1c in the liraglutide group and a 10% decrease in the pioglitazone group, suggesting a systemic metabolic benefit extending to the brain.